Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Blumenfeld

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Cephalalgia : an International Journal of Headache|October 15, 2025
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trialPatricia Pozo-Rosich, Andrew M Blumenfeld, Richard B Lipton, et al.
Bioorganicheskaia Khimiia|January 1, 1994
[Synthesis of cyclic oligodeoxyribonucleotides with non-nucleotide inserts]T S Oretskaia, N G Dolinnaia, I N Merenkova, et al.
Headache|December 15, 2025
OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trialAndrew M Blumenfeld, Larry Charleston, Deena Kuruvilla, et al.
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
Headache|March 6, 2013
Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)Andrew M Blumenfeld, Lisa M Bloudek, Werner J Becker, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
Headache-related health resource utilisation in chronic and episodic migraine across six countriesJoanna C Sanderson, Emily B Devine, Richard B Lipton, et al.
Cephalalgia : an International Journal of Headache|June 22, 2011
The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristicsKrista A Payne, Sepideh F Varon, Ariane K Kawata, et al.
Headache|October 13, 2022
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycleDavid W Dodick, Andrew M Blumenfeld, Rashmi B Halker Singh, et al.
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Headache|January 27, 2023
Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trialStewart J Tepper, Liron Rabany, Robert P Cowan, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Cephalalgia : an International Journal of Headache|October 15, 2025
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trialPatricia Pozo-Rosich, Andrew M Blumenfeld, Richard B Lipton, et al.
Bioorganicheskaia Khimiia|January 1, 1994
[Synthesis of cyclic oligodeoxyribonucleotides with non-nucleotide inserts]T S Oretskaia, N G Dolinnaia, I N Merenkova, et al.
Headache|December 15, 2025
OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trialAndrew M Blumenfeld, Larry Charleston, Deena Kuruvilla, et al.
Cephalalgia : an International Journal of Headache|November 26, 2020
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implicationsPeter J Goadsby, Andrew M Blumenfeld, Richard B Lipton, et al.
Headache|March 6, 2013
Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)Andrew M Blumenfeld, Lisa M Bloudek, Werner J Becker, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
Headache-related health resource utilisation in chronic and episodic migraine across six countriesJoanna C Sanderson, Emily B Devine, Richard B Lipton, et al.
Cephalalgia : an International Journal of Headache|June 22, 2011
The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristicsKrista A Payne, Sepideh F Varon, Ariane K Kawata, et al.
Headache|October 13, 2022
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycleDavid W Dodick, Andrew M Blumenfeld, Rashmi B Halker Singh, et al.
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Headache|January 27, 2023
Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trialStewart J Tepper, Liron Rabany, Robert P Cowan, et al.
Pageof 12